Other languages Pluri Inc.

Equities

PLUR

US72942G2030

Market Closed - Nasdaq Other stock markets 02:00:00 27/04/2024 am IST			5-day change	1st Jan Change
5.357 ^USD	+9.33%		+2.04%	+15.55%

08/04	Sector Update: Health Care Stocks Decline Late Afternoon	MT
08/04	Sector Update: Health Care	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Decline Late Afternoon	09/04
Sector Update: Health Care	09/04
Pluri Receives US Patent for Immune Cell Expansion	08/04
Pluri Inc. Unveils A Novel Method for Expansion of Immune Cells Using Proprietary Technology	08/04
Pluri Selected as Cdmo by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing	14/03
Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation	11/03
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board	06/03
Pluri Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	13/02
Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis	23/01
Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division	08/01
Pluri Inc. Launches New Business Division Offering Cell Therapy Manufacturing Services as Contract Development and Manufacturing Organization: PluriCDMO	08/01
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction	21/12
Pluri Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	14/11
Pluri Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	13/23/13
Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation	16/23/16
Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors	13/23/13
Pluri Inc. Signs A Three Year $4.2 Million Contract with the U.S. National Institute of Allergy and Infectious Diseases	11/23/11
Pluri Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	10/23/10
Pluri Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	14/23/14
Pluri Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	11/22/11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Pluri Inc.

Equities

PLUR

US72942G2030

Other languages

Filters